London, 03 September 2014 – TechNavio, a global tech-focused research firm has added a report on the Global Hepatitis C Market 2014-2018 to its library of market research reports.
Hepatitis C is an RNA virus that belongs to the Flaviviridae family and predominantly affects the liver. The launch of direct acting antivirals (DAA) in this field has increased the efficacy of treatment, thus reducing the duration of therapy. It is anticipated that the treatment approach for chronic hepatitis C will rely heavily on DAAs in the coming years.
The new TechNavio report highlights market conditions contributing to a CAGR of 19.20 percent from 2013-2018. It also focuses on various market growth drivers, challenges, trends and detailed vendor analysis for key vendors including:
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- Vertex Pharmaceuticals Inc.
The TechNavio report focuses on developing trends like emergence of IFN-free regimens that are under development as all-oral regimens. These therapies are expected to attain higher sustained virological response (SVR) and cause fewer side effects than currently approved therapies.
“It is anticipated that the future treatment approach for chronic hepatitis C will rely heavily on direct acting antivirals. Currently, DAAs are usually prescribed in combination with PEG-IFN and ribavirin in order to provide more effective treatment,” says Faisal Ghaus, Vice President of TechNavio.
Key Information Covered in the Report:
- Market segmentation, size and forecast through 2018
- Key Geographies and Customer Segments
- Market Growth Drivers
- Market Challenges
- Market Trends
- Key Buying Criteria
- Key Vendors
https://www.technavio.com/%3Cp%3ETechNavio%20currently%20has%20more%20tha…
